Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele to Genotype Heart Disease Patients for Novartis

NEW YORK, Oct. 5 (GenomeWeb News) - ParAllele BioScience will genotype heart disease patients for Novartis Pharma, the South San Francisco-based company said today.


Under the agreement, ParAllele will discover new SNPs in candidate genes provided by Novartis, using its Mismatch Repair Detection technology. These SNPs will then be profiled across a large population of coronary artery disease patients and mateched controls to identify disease markers.


ParAllele will have the rights for diagnostic applications, while Novartis, which will pay for the study, plans to use the markers in drug discovery.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.